| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4fda45c540f11df3a7fe71d54a70562a |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 |
| filingDate |
2011-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6078e0e8692d0fcbe8432c5676a8fce7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b531472810a19ee0a5b1cf574713dc0e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15144665aa2cdfd620d3cabfae6367b7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2809cf9dcecea595aed9da2715a878ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6626e78d1fde8f325e8a7c2c4853922c |
| publicationDate |
2012-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CL-2011002467-A1 |
| titleOfInvention |
Compounds derived from 6- (3-aza-bicyclo [3.1.0] hex-3-yl) -2-phenylpyrimidines, antagonists of the p2y 12 receptor; pharmaceutical composition comprising them; and its use in the treatment of occlusive disorders. pct national phase. |
| abstract |
Compounds derived from 6- (3-aza-bicyclo [3.1.0] hex-3-yl) -2-phenylpyrimidines, antagonists of the adenosine 5'-diphosphate receptor (adp); pharmaceutical composition; and its use for the treatment of occlusive vascular disorders. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11634410-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10988463-B2 |
| priorityDate |
2009-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |